S'abonner

Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006 - 08/08/11

Doi : 10.1016/j.jaad.2008.09.035 
Jo-David Fine, MD, MPH, FRCP a, b, c, d, , Lorraine B. Johnson, MPH, ScD a, e, f, Madeline Weiner, RN a, f, Kuo-Ping Li, PhD g, Chirayath Suchindran, PhD g
a National Epidermolysis Bullosa Registry (NEBR), Nashville, Tennessee 
b Department of Medicine (Dermatology), Vanderbilt University School of Medicine, Nashville, Tennessee 
c Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee 
d Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 
e Department of Public Health Nursing, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 
f Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 
g Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 

Correspondence to: Jo-David Fine, MD, MPH, FRCP, Division of Dermatology, VMG Patterson Dermatology, 1900 Patterson St, Suite 100, Nashville, TN 37203.

Abstract

Background

Case series have demonstrated that potentially lethal cutaneous squamous cell carcinomas arise in patients with recessive dystrophic epidermolysis bullosa (RDEB), although the magnitude of this risk is undefined.

Methods

Systematic case finding and data collection were performed throughout the continental United States (1986-2002) by the National EB Registry on 3280 EB patients to determine cumulative and conditional risks for squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and malignant melanoma (MM) within each major EB subtype, as well as the cumulative risk of death from each tumor. Study design was cross-sectional, with a nested randomly sampled longitudinal subcohort (N = 450).

Results

SCCs arose primarily in RDEB, especially the Hallopeau-Siemens subtype (RDEB-HS), first beginning in adolescence. Less frequently, SCCs occurred in junctional EB (JEB). Cumulative risks rose steeply in RDEB-HS, from 7.5% by age 20 to 67.8%, 80.2%, and 90.1% by ages 35, 45, and 55, respectively. In Herlitz JEB, the risk was 18.2% by age 25. SCC deaths occurred only in RDEB, with cumulative risks in RDEB-HS of 38.7%, 70.0%, and 78.7% by ages 35, 45, and 55, respectively. MM arose in RDEB-HS, with a cumulative risk of 2.5% by age 12. BCCs arose almost exclusively in the most severe EB simplex subtype (Dowling-Meara) (cumulative risk = 43.6% by age 55).

Limitations

Mutational analyses were performed on only a minority of enrollees in the National EB Registry, preventing evaluation of the possible influence of specific genotypes on the risk of developing or dying from cutaneous SCCs.

Conclusions

SCC is the most serious complication of EB within adults, especially those with RDEB-HS. By mid-adulthood, nearly all will have had at least one SCC, and nearly 80% will have died of metastatic SCC despite aggressive surgical resection. When compared with SCCs arising within the normal population, the remarkably high risk of occurrence of and then death from SCCs among RDEB patients suggests likely differences in pathogenesis. Additional studies of EB-derived tumors and SCC cell lines may not only provide new insights into the mechanisms of carcinogenesis but also means whereby these particular tumors may be prevented or more effectively treated.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : BCC, DDEB, EB, EBS, EBS-DM, EBS-K, EBS-O, EBS-WC, JEB, JEB-H, JEB-nH, MM, NEBR, RDEB, RDEB-HS, RDEB-I, RDEB-nHS, SCC


Plan


 Supported by the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NO1 AM62271, NO1 AR22200, NO1 AR22201, NO1 AR72233, K24 AR02098).
 Reprints not available from the authors.
 Conflicts of interest: None declared.


© 2008  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 60 - N° 2

P. 203-211 - février 2009 Retour au numéro
Article précédent Article précédent
  • American Board of Dermatology Examination Dates
| Article suivant Article suivant
  • Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot study
  • Yasuo Kubota, Kozo Yoneda, Kozo Nakai, Junko Katsuura, Tetsuya Moriue, Yoshie Matsuoka, Izumi Miyamoto, Yukihiro Ohya

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.